LobbyingCampaign for Sustainable Drug Pricing lobbying by quarter
Campaign for Sustainable Drug Pricing's latest lobbying report covers Q4 2023, at $30K. Its first report covers Q4 2022; the issues it reports most are Copyright/Patent/Trademark and Medicare/Medicaid.
Campaign for Sustainable Drug Pricing
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $30K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Copyright, patent and trademark$50K · 5 reports
- Medicare and Medicaid$50K · 5 reports
- Pharmacy$50K · 5 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)5 reports
- Health & Human Services, Dept of (HHS)5 reports
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
- Food & Drug Administration (FDA)4 reports
- Patent & Trademark Office (PTO)4 reports
- Executive Office of the President (EOP)2 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| McDermott+ | $150K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| RODNEY WHITLOCK | 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood | Q4 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/19for Q4 2023 | McDermott+ | $30K |
| 23/10/16for Q3 2023 | McDermott+ | $30K |
| 23/07/19for Q2 2023 | McDermott+ | $30K |
| 23/04/20for Q1 2023 | McDermott+ | $30K |
| 23/01/13for Q4 2022 | McDermott+ | $30K |